MSN による配信

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript

Recursion Pharmaceuticals, Inc. (NASDAQ:RXRX) Q2 2025 Earnings Call Transcript August 5, 2025 Recursion Pharmaceuticals, Inc. misses on earnings expectations. Reported EPS is $-0.41187 EPS, ...
The Globe and Mail

Recursion Pharmaceuticals’ Earnings Call Highlights Growth and Challenges

Recursion Pharmaceuticals, Inc. recently held its earnings call, which conveyed an optimistic sentiment. The company is experiencing strong leadership transitions, maintaining a robust financial ...
Seeking Alpha

Recursion Pharmaceuticals, Inc. (RXRX) Q3 2025 Earnings Call Transcript

Hello, everybody, and welcome to Recursion's Third Quarter 2025 (L)earnings Call. My name is Chris Gibson. I'm the Co-Founder and current CEO of Recursion, and I'm so delighted to have you all joining ...
Yahoo Finance

Recursion Pharmaceuticals, Inc. (RXRX) Q2 FY2025 earnings call transcript

Earnings call Recursion ended the quarter with $533M in cash and reaffirmed its cash runway through Q4 2027. The company achieved a $7M milestone with Sanofi and expects over $100M in partnership ...
Yahoo Finance

Recursion Pharmaceuticals Inc (RXRX) Q4 2025 Earnings Call Highlights: Strategic Milestones ...

Cash Balance: Ended the year with $754 million in cash. Operating Expenses: 35% reduction in pro forma operating expenses year over year. 2026 Cash Operating Expenses: Expected to be under $390 ...
Seeking Alpha

Recursion to Report Fourth Quarter and Full Year 2025 Business Updates and Financial ...

Salt Lake City, UT, Feb. 18, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will provide ...